Compare Recursion Pharmaceuticals Inc (RXRX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while Wheaton Precious Metals Corp trades at $135.65 (market cap $60.46B). The key difference: Wheaton Precious Metals Corp is far larger — about 34× Recursion Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WPM | |
|---|---|---|
Market Cap | $1.78B | $60.46B |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $165.72 |
52-Week Low | $2.84 | $91.02 |
Enterprise Value | $1.30B | $62.34B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Wheaton Precious Metals (WPM) trades at $134.20, up 7.1% in 24 hours, near its pivot point of $134. The stock shows strong momentum with bullish moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.19 versus $1.15 estimated, driven by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income margins exceeding 64%, while valuation ratios like P/E of 29.77 reflect premium pricing. Analysts maintain an 80% buy rating with a $161.75 consensus target.
Outlook remains positive due to robust cash flow growth and exposure to rising gold/silver prices, but risks include commodity volatility and high valuations. Institutional buying supports upside, though technical indicators suggest near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
